Salix Pharma (SLXP) Misses Q3 EPS by 3c; Issues Weak Q4 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/7/2026
- Stocks close lower as investors eye Mideast talks, earnings
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- Sandisk unveils underwhelming outlook despite AI demand surge; shares slip
- Alphabet taps bond market with sweeping 10-part offering to fuel AI ambitions
- Citi says buy the pullback in memory stocks as upcycle is still in early innings
- Apollo to acquire easyJet for £5.7B in cash deal
- Nielsen to acquire DoubleVerify in merger deal
- Stocks close lower as investors eye Mideast talks, earnings
- The Trade Desk Inc. (TTD) Tops Q2 EPS by 16c, Misses on Revenue; Offers Weak Q3 Revenue Guidance
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Salix Pharmaceuticals (SLXP) Target Sliced to $119 at Piper Jaffray on Inventory Disaster
November 7, 2014 9:18 AM ESTPiper Jaffray analyst David Amsellem cut estimates and his price target on Salix Pharmaceuticals (NASDAQ: SLXP) to $119.00 (from $189.00) while maintaining an Overweight rating.
Amsellem commented, "It is now clear that Salixs management (or rather mismanagement) of inventory has been an unmitigated disaster that will depress... More
Salix Pharmaceuticals (SLXP) Price Target Reduced to $102 at Goldman Sachs
November 7, 2014 8:58 AM ESTGoldman Sachs maintained a Neutral rating on Salix Pharmaceuticals (NASDAQ: SLXP) and lowered its price target to $102.00 (from $147.00). The change follows a disappointing Q3 update and the resignation of its CFO.
"3Q was clearly disappointing, but even more surprising was SLXPs revelation of how high its inventory levels are for key products and how that will dramatically impact... More
Jefferies Slashes Estimates and Price Target on Salix Pharmaceuticals (SLXP); Keeps 'Buy'
November 7, 2014 7:17 AM ESTJefferies analyst David Steinberg slashed his price target on Salix Pharmaceuticals (NASDAQ: SLXP) to $103.00 (from $177.00) following Q3 results but maintained a Buy rating.
Steinberg commented, "SLXP reported Q3 financials that again suffered materially from inventory management issues. Far overshadowing this, the company disclosed... More
William Blair Downgrades Salix Pharmaceuticals (SLXP) to Market Perform
November 7, 2014 7:16 AM ESTWilliam Blair downgraded Salix Pharmaceuticals (NASDAQ: SLXP) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Salix Pharmaceuticals click here. For more ratings news on Salix Pharmaceuticals click here.
Shares of Salix Pharmaceuticals closed at $138.55 yesterday.
... MoreStifel Downgrades Salix Pharmaceuticals (SLXP) to Hold
November 7, 2014 7:15 AM ESTStifel downgraded Salix Pharmaceuticals (NASDAQ: SLXP) from Buy to Hold.
For an analyst ratings summary and ratings history on Salix Pharmaceuticals click here. For more ratings news on Salix Pharmaceuticals click here.
Shares of Salix Pharmaceuticals closed at $138.55 yesterday.
... MoreMizuho Securities Downgrades Salix Pharmaceuticals (SLXP) to Neutral
November 7, 2014 7:15 AM ESTMizuho Securities downgraded Salix Pharmaceuticals (NASDAQ: SLXP) from Buy to Neutral.
For an analyst ratings summary and ratings history on Salix Pharmaceuticals click here. For more ratings news on Salix Pharmaceuticals click here.
Shares of Salix Pharmaceuticals closed at $138.55 yesterday.
... MoreSalix Pharma (SLXP) CFO Derbyshire Resigns
November 6, 2014 4:06 PM ESTSalix Pharma (NASDAQ: SLXP) announced the appointment of Timothy J. Creech as Acting Chief Financial Officer of the Company, effective immediately. He succeeds Adam C. Derbyshire, who resigned his position at the Company.
Mr. Creech, who joined the Company in 2007, has most recently been serving as the Companys Senior Vice President, Finance and... More
Salix Pharma (SLXP) trading halted with news pending
November 6, 2014 4:01 PM ESTSalix Pharma (NASDAQ: SLXP) trading halted with news pending.
... More